MRSN vs. ATYR, IMMP, OLMA, KRRO, NMRA, YMAB, KOD, TVGN, NGNE, and ACIU
Should you be buying Mersana Therapeutics stock or one of its competitors? The main competitors of Mersana Therapeutics include Atyr PHARMA (ATYR), Immutep (IMMP), Olema Pharmaceuticals (OLMA), Korro Bio (KRRO), Neumora Therapeutics (NMRA), Y-mAbs Therapeutics (YMAB), Kodiak Sciences (KOD), Tevogen Bio (TVGN), Neurogene (NGNE), and AC Immune (ACIU). These companies are all part of the "pharmaceutical products" industry.
Mersana Therapeutics vs.
Mersana Therapeutics (NASDAQ:MRSN) and Atyr PHARMA (NASDAQ:ATYR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, community ranking, risk and valuation.
93.9% of Mersana Therapeutics shares are held by institutional investors. Comparatively, 61.7% of Atyr PHARMA shares are held by institutional investors. 11.8% of Mersana Therapeutics shares are held by company insiders. Comparatively, 3.7% of Atyr PHARMA shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Mersana Therapeutics has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500. Comparatively, Atyr PHARMA has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500.
Atyr PHARMA has lower revenue, but higher earnings than Mersana Therapeutics. Atyr PHARMA is trading at a lower price-to-earnings ratio than Mersana Therapeutics, indicating that it is currently the more affordable of the two stocks.
Mersana Therapeutics received 239 more outperform votes than Atyr PHARMA when rated by MarketBeat users. However, 100.00% of users gave Atyr PHARMA an outperform vote while only 66.05% of users gave Mersana Therapeutics an outperform vote.
Mersana Therapeutics currently has a consensus price target of $5.57, indicating a potential upside of 983.94%. Atyr PHARMA has a consensus price target of $18.60, indicating a potential upside of 325.14%. Given Mersana Therapeutics' higher possible upside, equities analysts clearly believe Mersana Therapeutics is more favorable than Atyr PHARMA.
Atyr PHARMA has a net margin of 0.00% compared to Mersana Therapeutics' net margin of -214.20%. Atyr PHARMA's return on equity of -79.44% beat Mersana Therapeutics' return on equity.
In the previous week, Atyr PHARMA had 11 more articles in the media than Mersana Therapeutics. MarketBeat recorded 14 mentions for Atyr PHARMA and 3 mentions for Mersana Therapeutics. Atyr PHARMA's average media sentiment score of 0.89 beat Mersana Therapeutics' score of 0.45 indicating that Atyr PHARMA is being referred to more favorably in the news media.
Summary
Mersana Therapeutics beats Atyr PHARMA on 9 of the 17 factors compared between the two stocks.
Get Mersana Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mersana Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:MRSN) was last updated on 2/22/2025 by MarketBeat.com Staff
Free MRSN Stock Alerts